Purdue Pharma taps financial restructuring firm; White House wants opioid-production cut; NYU to make med school free.
For Gideon, honoring those who helped build the medical ad industry became a labor of love.
Teva's generic EpiPen injector received a thumbs up from the FDA on Thursday.
The study estimated the FDA's anti-smoking campaign, The Real Cost, saved $31 billion in smoking-related costs to society.
CDC estimates 72,000 died of drug overdoses in 2017; Genentech to lay off 200-plus employees; Pfizer invests up to $425 million in BioNTech.
Alphabet invests more in Oscar; ViiV's HIV injection proves effective; Gilead's chief medical officer departs in latest executive exit.
Moosmayer is set to join the pharma company in December.
Bigger budgets, fewer accounts. That's the dilemma facing pharma marketers as drugmakers consolidate work.
Icahn drops bid to stop Cigna-Express Scripts tie-up; Bayer joins Evotec-Haplogen partnership to find COPD treatments; Orchard raises $150 million in Series C funding.
WPP is set to depart its London headquarters in Farm Street after more than 30 years as it seeks "a more modern and attractive office."
Mohan was previously head of global drug-development communications.
Bayer shares fall after Monsanto weedkiller judgment; FDA approves first birth-control app to be marketed as contraception method; Regulators okay landmark RNAi-based therapy.
The first non-opioid opioid-withdrawal treatment, Lucemyra, hit the market this week.
FDA approves record number of generics in July; Trump drug-pricing policies may be hurting generic makers; Justice Department joins opioid lawsuit.
The point-of-care healthcare marketing company also conducted an initial study with Nielsen on its audience.